IRLAB is Granted an End-of-Phase 2 Meeting with the FDA for the Phase III-Ready Mesdopetam Program
GOTHENBURG, SWEDEN / ACCESSWIRE / January 3, 2024 / IRLAB Therapeutics (STO:IRLAB-A) (FRA:6IRA) Gothenburg, Sweden, January 3, 2024 - IRLAB...
Brain
Avenue Therapeutics Announces Completion of Enrollment in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy’s Disease)
- Topline data remains on track for second quarter of 2024 - MIAMI, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Avenue...
Neumora Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
WATERTOWN, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug...
Voyager Therapeutics Enters Capsid License Agreement and Strategic Collaboration with Novartis to Advance Novel Gene Therapies
- Collaboration with gene therapy leader Novartis aims to discover and develop new approaches for Huntington’s disease and spinal muscular...
Microbot Medical Announced Positive Results of Its GLP Pivotal Pre-Clinical Study Where All Study Objectives Were Met
The results of the study will support the Company’s IDE submission to the FDA to commence its human clinical studyBRAINTREE,...
NKGen Biotech Announces Clearance of Clinical Trial Application by Health Canada for SNK01 NK Cell Therapy to Treat Alzheimer’s Disease
NKGen’s SNK01 program continues to show positive progress with the FDA IND clearance in October 2023, and now the CTA...
Algernon Pharmaceuticals Announces Increase to Private Placement
VANCOUVER, British Columbia, Dec. 27, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the “Company” or...
Annexon Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
BRISBANE, Calif., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX) a clinical-stage biopharmaceutical company developing a new class...
IRLAB Extends CEO Appointment
GOTHENBURG, SWEDEN / ACCESSWIRE / December 27, 2023 / IRLAB Therapeutics (STO:IRLAB-A) (FRA:6IRA) Gothenburg, Sweden, December 27, 2023 - IRLAB...
U.S. Food and Drug Administration issues Complete Response Letter for dasiglucagon in congenital hyperinsulinism for up to three weeks of dosing due to inspection findings at third-party manufacturing facility
Company announcement – No. 45 / 2023 U.S. Food and Drug Administration issues Complete Response Letter for dasiglucagon in congenital...
Todos Medical Announces Insolvency Proceedings in Israel
NEW YORK, NY, ALPHARETTA, GA and TEL AVIV, Israel, Dec. 22, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd....
FSD Pharma Files Final Base Shelf Prospectus to Replace Expired Base Shelf Prospectus and Form F-3 Registration Statement with the SEC
TORONTO, ON / ACCESSWIRE / December 22, 2023 / FSD Pharma Inc. (NASDAQ:HUGE) (CSE:HUGE) (FRA:0K9A) ("FSD Pharma" or the "Company"),...
IRLAB Increases its Liquidity with a Loan Facility of Up to SEK 55 Million that Extends Financial Runway and Increases Business Opportunities
GOTHENBURG, SWEDEN / ACCESSWIRE / December 22, 2023 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA)(Nasdaq Stockholm:IRLAB A), a company discovering and developing novel...
IRLAB Receives Grant from The Michael J. Fox Foundation to Support Development of IRL757 for the Treatment of Apathy
GOTHENBURG, SWEDEN / ACCESSWIRE / December 21, 2023 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, December 21, 2023 - IRLAB Therapeutics...
IRLAB’s Drug Candidate IRL757 is Phase I Ready
GOTHENBURG, SWEDEN / ACCESSWIRE / December 21, 2023 / IRLAB Therapeutics (STO:IRLAB-A) (FRA:6IRA) Gothenburg, Sweden, December 21, 2023 - IRLAB...
MyndTec Inc. Completes Second Tranche of Non-Brokered Private Placement
Mississauga, Ontario--(Newsfile Corp. - December 20, 2023) - MyndTec Inc. (CSE: MYTC) ("MyndTec" or the "Company"), an emerging leader in...
Longeveron Announces Additional Positive Clinical Data and Imaging Biomarker Results from the CLEAR MIND Phase 2a Trial of Lomecel-B™ in the Treatment of Mild Alzheimer’s Disease
New clinical data showed that Lomecel-B™ improved cognitive function in multiple measures in a dose-response fashion Caregiver ratings documented improved quality...
IEEE EMBS Executive Committee Appoints Dr. Erika Ross Ellison as President-Elect, Along With Two New Vice Presidents
Dr. Beena Ahmed appointed vice president of Conferences Dr. Natalie Mrachacz-Kersting appointed vice president of Member and Student Activities Two-year...
Biodexa Announces Pricing of $5.2 Million Underwritten Public Offering
Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) CARDIFF, United Kingdom, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX),...
Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs
BOSTON and ATLANTA, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical...